Skip to main content

Advertisement

Fig. 1 | Clinical Epigenetics

Fig. 1

From: Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair

Fig. 1

The HDAC inhibitor chidamide synergistically interacts with the menin-MLL interaction inhibitor MI-3 to inhibit cell viability in MLL-r AML cells. a, b Human MLL-rearranged AML cell lines MOLM-13 (a) and MV4-11 cells (b) were exposed to the indicated concentrations (μM) of chidamide ± MI-3 (μM) for 24, 48, and 72 h, after which cell viability was examined using the CCK-8 assay. Values indicate mean ± SEM for at least three independent experiments performed in triplicate. *P < 0.05, **P < 0.01, and ***P < 0.001 for comparison with each single agent. c, d MOLM-13 (c) and MV4-11 (d) cells were treated as described in Additional file 2: Supplemental Table 1, followed by the analysis of cell viability as above, after which the CompuSyn analysis was performed to determine whether the interaction between these two agents is synergistic (CI value < 1.0)

Back to article page